Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of LEAP-2 on Glucose and Food Intake
NCT04621409Phase 1Completed
- Sponsor
- Gentofte Hospital
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing liver-enriched antimicrobial peptide 2 with Placebo (2 arms). Primary endpoint: Food intake. Started Nov 2020; status: completed.
02
Drugs
liver-expressed antimicrobial peptide 2
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04621409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621409.